(233) Development of TAM-targeted nanoparticles for immunotherapy in pancreatic cancer

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers. Its dense desmoplasia and immunosuppressive tumor microenvironment (TME) create barriers to drug delivery and immune cell infiltration. Tumor-associated macrophages (TAMs) play a key role in tumor progression and immune evasion. This study introduces a TAM-targeted nanoparticle to reprogram TAMs and modulate the TME to enhance anti-tumor immunity. Encapsulation of STING agonists in nanoparticles addresses limitations such as poor cellular uptake and short systemic half-life, improving their therapeutic efficacy in PDAC.